Eloise Phillips
Impact in
- Infectious Diseases top 1%
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- SARS-CoV-2 detection and testing
- Viral gastroenteritis research and epidemiology
- Animal Science and Zoology top 2%
- Animal Virus Infections Studies
Papers in
-
- SARS-CoV-2 and COVID-19 Research 10
- COVID-19 Clinical Research Studies 5
- Viral gastroenteritis research and epidemiology 1
-
- Immunotherapy and Immune Responses 2
Eloise Phillips
12 papers receiving 1.9k citations
Eloise Phillips's Hit Papers
Peers
Comparison fields: 5 of 75
- Infectious Diseases 1.7k
- Animal Science and Zoology 227
- Modeling and Simulation 79
- Health 108
- Immunology 240
Countries citing papers authored by Eloise Phillips
This map shows the geographic impact of Eloise Phillips's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eloise Phillips with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eloise Phillips more than expected).
Fields of papers citing papers by Eloise Phillips
This network shows the impact of papers produced by Eloise Phillips. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eloise Phillips. The network helps show where Eloise Phillips may publish in the future.
No co-authors to show.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses Hit paper breakdown → | 2022 | 740 |
| 2 | Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum Hit paper breakdown → | 2022 | 547 |
| 3 | Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine Hit paper breakdown → | 2021 | 249 |
| 4 | 2021 | 131 | |
| 5 | 2021 | 129 | |
| 6 | 2023 | 82 | |
| 7 | 2023 | 30 | |
| 8 | 2022 | 15 | |
| 9 | 2023 | 13 | |
| 10 | 2022 | 7 | |
| 11 | 2025 | 4 | |
| 12 | 2024 | 3 |
About Eloise Phillips
Eloise Phillips is a scholar working on Infectious Diseases, Immunology, Animal Science and Zoology, Oncology and Hematology, having authored 12 papers that have together received 1.9k indexed citations. Recurring topics across this work include SARS-CoV-2 and COVID-19 Research (10 papers), COVID-19 Clinical Research Studies (5 papers), Animal Virus Infections Studies (2 papers), CAR-T cell therapy research (2 papers), Immunotherapy and Immune Responses (2 papers), Viral gastroenteritis research and epidemiology (1 paper), vaccines and immunoinformatics approaches (1 paper) and Hematopoietic Stem Cell Transplantation (1 paper). The work is most often cited by research in Infectious Diseases (1.7k citations), Animal Science and Zoology (227 citations), Modeling and Simulation (79 citations), Health (108 citations) and Immunology (240 citations). Eloise Phillips has collaborated with scholars based in United Kingdom, China and Thailand. Their work appears in journals such as Cell, British Journal of Haematology, Clinical & Experimental Immunology, Nature Communications and Nature Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.